Otsuka's VOYXACT shows two-year kidney benefit in push for full US approval
Positive phase 3 data move the IgA nephropathy treatment beyond its earlier proteinuria-based accelerated approval, while leaving Otsuka's outlook for the year ending December 2026 unchanged.